|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.260 USD | -0.84% |
|
-12.68% | +14.56% |
| 06-09 | Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases | MT |
| 05-26 | Cartesian Therapeutics, Inc. Announces Executive Changes | CI |
| Market Cap | 243M 212M 196M 180M 340M 23.37B 348M 2.34B 920M 11.45B 911M 891M 39.4B | P/E 2026 * |
-1.99x | P/E 2027 * | -2.16x |
|---|---|---|---|---|---|
| Enterprise Value | 99.19M 86.68M 79.99M 73.73M 139M 9.55B 142M 956M 376M 4.68B 373M 364M 16.1B | EV / Sales 2026 * |
180x | EV / Sales 2027 * | -148x |
| Free-Float |
46.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cartesian Therapeutics, Inc.
| 1 day | -0.84% | ||
| 1 week | -12.68% | ||
| Current month | -20.73% | ||
| 1 month | -14.23% | ||
| 3 months | +17.33% | ||
| 6 months | +11.32% | ||
| Current year | +14.56% |
| 1 week | 8.02 |  | 9.19 |
| 1 month | 8.02 | | 11 |
| Current year | 5.6 | | 11 |
| 1 year | 5.6 | | 14.56 |
| 3 years | 5.6 | | 42.6 |
| 5 years | 5.6 | | 42.6 |
| 10 years | 5.6 | | 42.6 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02/04/26 | Fiscal year | 758,001 | 2.8594% | |||
| 02/04/26 | Fiscal year | 22,740 | - | |||
| 02/04/26 | Fiscal year | 22,740 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.84% | -12.68% | -30.24% | - | 243M | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.58% | -3.63% | +33.46% | +184.05% | 23.38B | |
| Weighted average by Cap. | -2.80% | -2.37% | +39.47% | +143.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 552K 483K 445K 410K 774K 53.18M 791K 5.32M 2.09M 26.05M 2.07M 2.03M 89.66M | 402K 351K 324K 298K 563K 38.67M 575K 3.87M 1.52M 18.94M 1.51M 1.47M 65.19M |
| Net income | -122M -107M -98.67M -90.94M -171M -11.78B -175M -1.18B -464M -5.77B -459M -449M -19.87B | -131M -114M -105M -97.17M -183M -12.59B -187M -1.26B -496M -6.17B -491M -480M -21.22B |
| Net Debt | -144M -125M -116M -107M -201M -13.82B -206M -1.38B -544M -6.77B -539M -527M -23.3B | -302M -264M -244M -225M -423M -29.09B -433M -2.91B -1.15B -14.25B -1.13B -1.11B -49.05B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | $8.260 | -0.84% | 145,321 |
| 16/07/26 | $8.330 | -4.03% | 126,075 |
| 15/07/26 | $8.680 | +0.70% | 180,453 |
| 14/07/26 | $8.620 | -0.12% | 114,470 |
| 13/07/26 | $8.630 | -8.77% | 259,974 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RNAC Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
